Navigating Service Transitions and Clinical Continuity in Adult ADHD Management
The management of Attention Deficit Hyperactivity Disorder, widely known as ADHD, represents a critical area of neurodevelopmental healthcare in Ireland. Historically regarded as a childhood condition, contemporary clinical research has firmly established that symptoms frequently persist into adulthood, affecting executive function, emotional regulation, and social interactions. As diagnostic awareness grows, a vast number of adults find themselves at a crossroads regarding their clinical management, particularly when moving between service providers, transitioning from adolescent to adult services, or migrating to Ireland from abroad with an existing diagnosis.
The concept of transfer of care encompasses the formal shifting of ongoing clinical responsibility and treatment management from one healthcare provider or clinical team to another. Navigating this process within the Irish healthcare ecosystem requires a detailed understanding of available clinical pathways, necessary documentation, and regulatory constraints surrounding medication. This report evaluates the mechanisms of care transfer for adults in Ireland, providing a comprehensive analysis of assessment tools, shared care arrangements with general practitioners, and the distinct challenges associated with various transition pathways.
1. Understanding ADHD Transfer of Care
Transfer of care refers to the structured process by which a patient with an established ADHD diagnosis shifts their treatment, monitoring, and prescribing protocols to a new clinical entity. This process is distinct from an initial assessment or diagnostic pathway, as the primary goal is to ensure continuity of treatment rather than establishing a new clinical diagnosis from baseline. In the context of the Irish healthcare environment, transfer of care predominantly falls into several recognisable scenarios.
The first major scenario involves individuals transitioning from Child and Adolescent Mental Health Services, widely known as CAMHS, to adult psychiatric services upon reaching the age of majority. The second scenario involves patients transferring between private providers, often motivated by wait times, pricing structures, or geography. The third frequent scenario involves international migration, where individuals diagnosed in other jurisdictions seek to continue their established treatment regimens upon arrival in Ireland.
A successful transfer of care ensures that individuals do not experience gaps in their treatment, which could otherwise lead to significant functional impairment in academic, professional, and personal domains. Given the complexity of the Irish mental health framework and the severe shortage of public adult services, understanding the specific prerequisites for each pathway is essential for maintaining therapeutic stability.
2. Transitions from Child to Adult Services
The transition from youth centred mental health services to adult systems represents one of the most vulnerable periods for individuals undergoing ADHD management. In Ireland, CAMHS provides care for children and adolescents up to the age of eighteen, at which point clinical responsibility must transfer to adult services.
According to guidelines issued by the Health Service Executive, transition planning should ideally begin approximately one year before a young person finishes school, with formal transfer protocols initiated six months prior to their eighteenth birthday. The objective of this timeline is to provide ample opportunity to establish contact with adult services and minimise the risk of a treatment gap.
Despite these structural guidelines, the reality of public adult ADHD services in Ireland presents significant obstacles. Historically, there were no dedicated public adult ADHD services in the country prior to the launch of the National Clinical Programme in 2021. The Model of Care launched in 2021 outlined plans to establish eleven specialised adult teams nationwide. However, by 2023, only a fraction of these teams were fully operational, and significant geographical gaps remained.
In areas where a dedicated adult ADHD service has not yet been established, general adult psychiatrists may be tasked with taking over care. However, many general adult psychiatrists in Ireland have not historically received mandatory training in adult ADHD assessment and management during their specialist accreditation, leading to situations where adult services feel ill equipped to accept these transfers. Consequently, many young adults reaching the age of eighteen face a care cliff, where CAMHS cannot retain them and adult services cannot yet accept them, forcing many back to their general practitioners or into the private sector to maintain their prescriptions.
3. Transferring Between Private Providers
Due to the constraints and long waiting lists associated with the public health system, a substantial proportion of adults in Ireland seek care through private clinical channels. Individuals who have already secured a diagnosis through another private provider frequently seek to transfer their care to this clinic to avail of its structured aftercare ecosystem, therapy options, and rapid access to consultant psychiatrists. This applies equally to patients currently with alternative private providers who wish to switch.
The transfer pathway established here is designed to be streamlined, ensuring that those with an existing valid diagnosis can transition safely and efficiently. The pathway begins with an initial intake process priced at eighty nine euro, followed by a formal transfer appointment with a consultant psychiatrist at two hundred and fifty euro. For those requiring ongoing medical management, a monthly repeat prescription fee of fifteen euro applies thereafter.
To facilitate this transfer, patients must provide a formal, written diagnostic report originating from a registered psychiatrist or a chartered psychologist. This report serves as clinical verification of the diagnosis. During the transfer appointment, the consultant psychiatrist conducts a comprehensive review of the patient’s psychiatric history, confirms the diagnosis against established clinical criteria, and reviews current medication dosages and efficacy. This thorough assessment ensures that the treatment plan remains appropriate and safe as clinical responsibility shifts to the new provider.
4. Relocating to Ireland with an Existing Diagnosis
Migration patterns frequently bring individuals with established ADHD diagnoses to Ireland, including professionals and students attending institutions such as Trinity College Dublin or University College Cork. International transfers introduce a unique layer of complexity, primarily dictated by differences in global pharmaceutical regulations and the specific availability of medications within the Irish state.
A critical concern for individuals relocating from non European jurisdictions, particularly the United States, is the local availability of specific stimulant medications. For instance, mixed amphetamine salts, widely known under the brand name Adderall, have never been approved by the European Medicines Agency due to regulatory philosophies favouring more conservative risk benefit thresholds regarding amphetamine abuse potential. Consequently, Adderall cannot be prescribed or dispensed in Ireland. Individuals arriving with an Adderall prescription will inevitably require a clinical reassessment and a transition to an alternative authorised medication, such as methylphenidate or lisdexamfetamine.
Furthermore, strict regulations govern the physical transport of controlled substances into the country. Since April 2023, individuals travelling from within the Schengen Area must possess an Article 75 Schengen Certificate for prescribed narcotics or psychotropic substances. For those arriving from non Schengen countries, customs officers require documented proof that the medication is for personal use, usually in the form of original packaging clearly labelled with the patient’s name, a valid prescription, and a formal letter from the prescribing physician detailing the diagnosis and dosage.
University specific pathways also exist to support students. For example, the College Health Service at Trinity College Dublin seeks to support ongoing clinical care for students with established diagnoses who are in a stable, established care plan. However, such services generally do not offer initial assessments or medication titration, necessitating that students arrive with comprehensive documentation from their home psychiatrists.
5. Required Documentation for Clinical Transitions
A transfer of care cannot proceed effectively without comprehensive documentation that substantiates the existing diagnosis and chronicles the patient’s treatment trajectory. Private clinics and public services alike operate under strict clinical governance, meaning that clinical responsibility cannot be assumed purely on a patient’s self report of a previous diagnosis.
The foundational requirement for any transfer of care is a formal, written diagnostic report. This report must be authored by a consultant psychiatrist or a chartered psychologist authorised to make such neurodevelopmental diagnoses. A summary letter or a copy of a prescription alone is generally insufficient, as clinical teams must evaluate the methodology and diagnostic criteria utilised during the original assessment to confirm its validity.
In addition to the formal diagnostic report, the transferring clinician will require explicit details regarding the current medication regimen, including the precise name of the pharmaceutical compound, the specific dosage, and frequency of administration. Any previous psychiatric correspondence, collateral information from childhood, or records of historical medication trials should also be compiled and presented. Having these documents organised beforehand significantly reduces administrative delays and ensures a seamless transition of clinical responsibility.
To further guide patients and professionals on the exact expectations of clinical documentation required for a smooth transition, the following data provides a structured comparison of necessary files.
| Document Type | Source Required | Purpose in Transfer |
| Formal Diagnostic Report | Psychiatrist or Chartered Psychologist | Confirms validity of original diagnosis |
| Current Prescription | Dispensing Doctor or Pharmacist | Establishes current active medication regimen |
| Psychiatric Correspondence | Previous Clinical Team | Provides longitudinal history of treatment |
| Childhood Collateral | Parents or School Records | Supports historical onset requirements |
6. Validated Tools in Adult ADHD Assessment
When a transfer of care takes place, the receiving clinician must often review the patient’s symptom profile to ensure that the ongoing treatment strategy remains clinically indicated. While a transfer does not usually necessitate a complete diagnostic overhaul, validating current symptom severity and historical onset is paramount for clinical governance.
In adult assessments, specific psychometric tools are widely recognised for their validity and reliability. It is critical to note that this clinic does not utilise the computerised QB test or the Conners Adult ADHD Rating Scales, known as CAARS, in its adult assessment process. Instead, three specific instruments are deployed to capture current symptomatology, retrospective childhood manifestations, and potential overlapping psychiatric conditions.
6.1. The Adult ADHD Self Report Scale
The Adult ADHD Self Report Scale version 1.1, commonly abbreviated as ASRS, is an eighteen item questionnaire developed in collaboration with the World Health Organization and researchers at Harvard Medical School. Grounded in the diagnostic criteria of the DSM, the scale is specifically worded to reflect how symptoms manifest in the context of adult responsibilities, replacing references to play or schoolwork with vocational and daily organisational demands.
The scale is divided into two parts. Part A consists of six questions that have been found to be the most predictive of symptoms consistent with ADHD in adults. These items evaluate difficulties such as wrapping up the final details of a complex project, maintaining organisational systems, remembering obligations, avoiding tasks that require sustained mental effort, fidgeting when required to sit still, and feeling an internal compulsion to remain active as if driven by a motor. If an individual scores high on at least four of these six items, there is a high probability that clinical ADHD is present, warranting deeper investigation.
Part B contains the remaining twelve questions, providing additional clinical cues regarding symptom frequency across broader domains of inattentiveness, hyperactivity, and impulsivity. These items probe into careless mistakes, difficulty sustaining attention on repetitive work, problems concentrating when spoken to directly, misplacing items, distractibility by external noise, leaving one’s seat in meetings, general restlessness, difficulty unwinding during leisure time, talking excessively, finishing the sentences of others, difficulty waiting your turn, and intruding on others.
The scoring methodology of the ASRS has evolved, shifting from a binary system to a five point Likert scale ranging from zero to four, corresponding to frequencies of never, rarely, sometimes, often, and very often. This gradation provides clinicians with a more nuanced assessment of symptom severity and serves as an excellent metric for tracking treatment efficacy over time.
| ASRS Part A Score Range | Clinical Interpretation | Recommended Action |
| Zero to Nine | Low probability of adult ADHD | Continue monitoring alternative causes |
| Ten to Thirteen | Mild to moderate symptom load | Investigate situational stressors |
| Fourteen to Seventeen | High probability of adult ADHD | Proceed to full diagnostic clinical interview |
| Eighteen or higher | Very high clinical probability | Direct clinical intervention indicated |
6.2. The Wender Utah Rating Scale
To secure a valid diagnosis of ADHD in adulthood, clinical guidelines mandate the establishment of childhood onset of symptoms. In many instances, adults seeking evaluation lack access to their original school reports or cannot obtain corroborating reports from parents or guardians. The Wender Utah Rating Scale twenty five item version, known as WURS 25, was developed to address this specific diagnostic requirement retrospectively.
Adapted from an original sixty one item scale pioneered by researchers specialising in the Utah criteria for ADHD, the shortened twenty five item version focuses on the most predictive behavioural and emotional indicators of childhood ADHD. Patients are instructed to rate their recollection of their behaviour up to the age of twelve on a scale of zero to four, representing a range from not at all to very much.
The WURS 25 is uniquely valuable because it captures domains beyond simple inattention and physical hyperactivity, aligning with the broader clinical picture often seen in neurodivergent children. Factor analyses of the scale generally reveal three primary domains. The first is dysthymia, which measures childhood emotional difficulties such as worry, sadness, low self perception, and feelings of guilt or regret. The second is oppositional defiant behaviour, evaluating irritability, hot tempers, outbursts, stubbornness, and disobedience towards authority figures. The third domain reflects school problems, including concentration deficits, daydreaming, failing to finish tasks, and achieving below one’s potential.
A total score of forty six or higher on the WURS 25 is generally considered the validated cutoff suggesting a positive screen for childhood ADHD. However, clinicians interpret these scores cautiously. Because emotional items are included, high scores can sometimes be inflated by childhood histories of depression, anxiety, or trauma. Thus, the WURS 25 functions as a supportive instrument within a broader multi method diagnostic approach rather than as a standalone diagnostic tool.
| WURS 25 Factor Domain | Clinical Elements Measured | Diagnostic Relevance |
| Dysthymia Factor | Sadness, negative self perception, guilt | Identifies childhood emotional comorbidities |
| Oppositional Factor | Outbursts, stubbornness, disobedience | Maps childhood behavioural dysregulation |
| School Problems Factor | Distractibility, low potential, poor math | Tracks academic executive dysfunction |
6.3. The Weiss Symptom Record
The Weiss Symptom Record II, or WSR II, is a comprehensive one hundred and twenty three item screening tool designed by Dr Margaret Weiss. While the ASRS and the WURS 25 focus specifically on the core diagnostic pillars of ADHD, the WSR II is deployed to capture a vast landscape of overlapping symptoms and coexisting psychiatric disorders. High rates of comorbidity are a defining feature of adult ADHD, with many individuals experiencing concurrent anxiety, depression, sleep disorders, or personality vulnerabilities.
The WSR II evaluates symptoms across nineteen distinct subscales. These include foundational domains of attention deficit, hyperactivity, and impulsivity, but extend widely into oppositional behaviours, learning difficulties, elements of the autism spectrum, motor disorders such as tics, and potential indicators of psychosis. Additionally, the scale evaluates mood regulation, depressive symptoms, anxiety profiles, stress related disorders, post traumatic stress, sleep architecture disruptions, eating patterns, conduct issues, substance use tendencies, and personality traits.
By utilising a Likert scale where items are rated as none, mild, moderate, or severe, the WSR II allows clinicians to identify which clusters of symptoms are clinically significant. Any symptom cluster falling into the moderate or severe range is flagged as problematic, signalling to the clinician that further investigation or specialised diagnostic assessment is required in that specific domain. While the WSR II cannot be used to yield a formal diagnosis by itself, its value lies in its ability to map a highly detailed and individualised symptom architecture, ensuring that the treatment plan is holistic and accounts for comorbidities rather than addressing ADHD in clinical isolation.
7. The Shared Care Model and Primary Care Integration
Upon the successful transfer of care to a specialist provider and the stabilisation of treatment, many adults look to transition the ongoing administrative burden of their care to their primary care physician. This process is executed through a shared care model, which serves as a highly effective mechanism for distributing clinical responsibilities between specialised psychiatric services and general practitioners.
Under a shared care agreement, the consultant psychiatrist at the specialised clinic retains the responsibility for the initial assessment, the formal diagnosis, and the titration of medication until the patient achieves clinical stability on an established dosage. Once stability is achieved and documented, the specialist outlines a protocol under which the general practitioner takes over the responsibility for issuing monthly prescriptions and performing routine physical monitoring, such as tracking blood pressure and heart rate, which are standard safety parameters for individuals on stimulant medications.
A crucial point for patients to understand is that shared care operates strictly at the discretion of the individual general practitioner. There is no legal or regulatory mandate in Ireland that forces a general practitioner to accept a shared care agreement. Some primary care physicians feel comfortable managing prescriptions for controlled neurodevelopmental medications, while others may cite a lack of specialised training or concerns regarding clinical liability and refuse to participate.
To facilitate this process and maximise the likelihood of a positive outcome, clinics provide a formalised Shared Care Agreement document. This document clearly outlines the clinical responsibilities of both parties, provides guidance on monitoring parameters, and establishes a direct channel of communication so the general practitioner can refer the patient back to the consultant psychiatrist should symptoms destabilise or complications arise.
8. Workplace Protections and the Legal Landscape of Disability
Beyond clinical assessment tools, understanding the regulatory and legal frameworks active in Ireland is essential for anyone undergoing a transfer of care. The Irish state possesses specific laws regarding disability protections, as well as distinct challenges regarding pharmaceutical supply chains that can directly impact an individual’s therapeutic continuity.
Under the Employment Equality Acts 1998 to 2015, individuals with ADHD are protected against discrimination in the workplace, as the condition can be legally recognised as a disability depending on the severity of its impact on daily functioning. This legal framework guarantees that employees with ADHD have rights during recruitment, promotion, and daily operations. Furthermore, employers are prompted to provide reasonable accommodations to enhance work performance. Such accommodations might include granting flexible working hours, providing a quiet workspace to minimise distractions, supplying software tools for organisational task management, and allowing extra time for complex project completion. Understanding these rights is an important aspect of holistic adult ADHD management after clinical stabilisation.
9. Medicine Shortages and Market Vulnerabilities in Ireland
From a pharmacological perspective, patients must also be aware of the intermittent medicine shortages that have affected the Irish market in recent years. The Health Products Regulatory Authority, known as the HPRA, monitors and publishes up to date lists of medicine shortages impacting the country. Supply interruptions have occasionally affected various formulations containing active ingredients such as methylphenidate, lisdexamfetamine, atomoxetine, and guanfacine. These shortages are largely driven by massive surges in global demand paired with manufacturing delays and the low pricing paid for generics by the state schemes, making Ireland a less commercially viable market for some suppliers.
When a specific strength or brand becomes unavailable, patients must coordinate closely with their treating clinician and pharmacist. In many instances, the HPRA allows regulatory flexibilities, such as permitting authorised wholesalers to source equivalent medications from other European markets to bridge the gap. If a direct substitute is unavailable, the prescribing psychiatrist may need to calculate an equivalent dosage of a similar medication to ensure that treatment remains uninterrupted.
To contextualise how these pharmaceutical ingredients are deployed in clinical practice across Ireland, the following data delineates the active compounds and their specific applications.
| Active Ingredient | Therapeutic Category | Typical Application in Ireland |
| Methylphenidate | Central nervous system stimulant | Standard first line therapy for focus management |
| Lisdexamfetamine | Central nervous system stimulant | Prolonged release compound for sustained coverage |
| Atomoxetine | Non stimulant medication | Ideal for co occurring anxiety or misuse history |
| Guanfacine | Non stimulant medication | Modulates alpha receptors for impulse control |
10. Conclusions and Strategic Guidance
Navigating the transfer of ADHD care in Ireland reveals a complex interaction between clinical governance, regulatory constraints, and systemic shortages in public health service capacity. The transition of care is not merely an administrative shift but a critical clinical protocol that requires thorough documentation, standardised assessment, and active communication between specialists, patients, and primary care physicians.
For individuals seeking a seamless transfer of care, several strategic guidelines emerge from the data. Patients must proactively gather all necessary documentation, ensuring they possess a formal, written diagnostic report from a registered psychiatrist or chartered psychologist before initiating the transfer process. Relying on basic summary letters or prescriptions alone frequently leads to delays.
Individuals relocating to Ireland from abroad must review their current medication against European regulatory standards. Recognising that specific compounds like Adderall are not available in Ireland allows patients to prepare for a planned clinical titration onto approved alternatives without experiencing abrupt gaps in their functional support.
Patients intending to utilise shared care must engage with their general practitioners early. Since shared care is entirely at the physician’s discretion, identifying whether a general practitioner will accept clinical responsibility for issuing monthly prescriptions prevents administrative bottlenecks after specialist stabilisation is achieved.
Ultimately, while the public healthcare system in Ireland continues to work toward expanding its adult ADHD service footprint to fulfil the goals of the National Clinical Programme, private clinical pathways remain the primary mechanism for many adults to achieve timely, reliable, and expert led continuity of care. By understanding the clinical instruments utilised, such as the Adult ADHD Self Report Scale, the Wender Utah Rating Scale, and the Weiss Symptom Record, and by navigating the regulatory parameters of the state, adults can successfully safeguard their clinical management and continue to thrive across all domains of life.
Works Cited
HSE National Clinical Programme for Adults with ADHD. Available at: [LINK]
National Clinical Programme Clinical Efficacy Evaluation. Available at: [LINK]
Medical Independent on Gaps in Public ADHD Services. Available at: [LINK]
Oireachtas Parliamentary Debates regarding Adult ADHD Programmes. Available at: [LINK]
ADHD Ireland Resources and Support for Adults. Available at: [LINK]
NovoPsych Adult ADHD Self Report Scale Overview. Available at: [LINK]
NovoPsych Wender Utah Rating Scale Overview. Available at: [LINK]
Health Products Regulatory Authority on Medicines Shortages. Available at: [LINK]
Department of Health Traveling into Ireland with Controlled Drugs. Available at: [LINK]
Trinity College Dublin Student Health Service Policy. Available at: [LINK]